Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Drug Profile

Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics

Alternative Names: PROSTVAC; PROSTVAC-F; PROSTVAC-V; PROSTVAC-VF-TRICOM; PSA-TRICOM; Rilimogene gamvacirepvec-rilimogene glafolivec; Rilimogene-glafolivec-rilimogene-galvacirepvec; Vaccinia PSA TRICOM-fowlpox PSA TRICOM

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
  • Class Antineoplastics; Cancer vaccines; Gene therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 05 Sep 2018 Washington University School of Medicine and Bristol-Myers Squibb initiates a phase I trial for Prostate Cancer (Late stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT03532217)
  • 13 Jun 2018 Immunogenicity data from a clinical trial in Prostate cancer presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 01 Jun 2018 Immunogenicity data from a phase II trial in Prostate cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top